Vincent J L, Brimioulle S, Berre J, Kahn R J
Crit Care Med. 1985 Oct;13(10):783-5. doi: 10.1097/00003246-198510000-00002.
Because the formation of platelet thrombi has been incriminated in the development of the adult respiratory distress syndrome (ARDS), we tested the hypothesis that early administration of antiplatelet agents might protect the lungs in patients at risk to develop ARDS after circulatory shock. This double-blinded study included 40 patients treated with either 3 mg/kg . 24 h of dipyridamole or a corresponding dose of placebo after an episode of hemorrhagic, traumatic, or septic shock. Each patient also received 100 mg of aspirin daily. Arterial blood gases and chest x-rays were not significantly different between dipyridamole and placebo groups. Moreover, two patients receiving dipyridamole but none receiving placebo developed ARDS. This pilot study does not support a beneficial effect of dipyridamole in the prevention of ARDS after circulatory shock.
由于血小板血栓的形成被认为与成人呼吸窘迫综合征（ARDS）的发生有关，我们检验了这样一个假设：对于循环休克后有发生ARDS风险的患者，早期给予抗血小板药物可能会保护肺部。这项双盲研究纳入了40例患者，这些患者在经历出血性、创伤性或感染性休克后，接受了3 mg/kg·24小时的双嘧达莫治疗或相应剂量的安慰剂治疗。每位患者还每日服用100 mg阿司匹林。双嘧达莫组和安慰剂组之间的动脉血气和胸部X光检查结果无显著差异。此外，接受双嘧达莫治疗的两名患者发生了ARDS，而接受安慰剂治疗的患者无一发生ARDS。这项初步研究不支持双嘧达莫在预防循环休克后ARDS方面具有有益作用。
